



PATENT

Case Docket No. ABGENIX.057A

Date: June 23, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Zapata, Gerardo  
Appl. No. : 10/688,198  
Filed : October 17, 2003  
For : SYSTEM AND METHOD FOR  
CLEAVING ANTIBODIES  
Examiner : Unassigned  
Group Art Unit : 1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 23, 2004

(Date)

Erik T. Anderson, Reg. No. 52,559

TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirteen (13) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Erik T. Anderson  
Registration No. 52,559  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant(s) : Zapata, Gerardo  
Appl. No. : 10/688,198  
Filed : October 17, 2003  
For : SYSTEM AND METHOD FOR  
CLEAVING ANTIBODIES  
Examiner : Unassigned  
Group Art Unit : 1644

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing thirteen (13) references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6/23/04

By:   
Erik T. Anderson  
Registration No. 52,559  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
ABGENIX.057AAPPLICATION NO.  
10/688,198INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Zapata, GerardoFILING DATE  
October 17, 2003GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1	4,735,210	04/05/88	Goldenberg			
	2	5,101,827	04/07/92	Goldenberg			
	3	5,102,990	04/07/92	Rhodes			
	4	Re. 35,500	05/06/97	Rhodes			
	5	5,194,594	03/16/93	Khawli, et al.			
	6	5,648,471	07/15/97	Buttram, et al.			
	7	5,697,902	12/16/97	Goldenberg			
	8	6,066,719	05/23/00	Zapata			

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	9	<i>Cancer Chemotherapy and Biotherapy: Principles and Practice</i> , 2 <sup>nd</sup> Edition, Chabner and Longo eds., Lippincott-Raven Publishers, Philadelphia, pp. 655-689, (1996).
	10	Kearney, et al., "A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines", <i>The Journal of Immunology</i> , vol. 123, no. 4, pp. 1548-1550, (October 1979).
	11	Urlaub, et al., "Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells", <i>Cell</i> , vol. 33, pp. 405-412, (June 1983).
	12	Urlaub, et al., "Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions", <i>Somatic Cell and Molecular Genetics</i> , vol. 12, no. 6, pp. 555-566, (1986).
	13	Vitetta, et al., "Immunotoxins: magic bullets or misguided missiles?", <i>Immunology Today</i> , vol. 14, no. 6, pp. 252-259, (1993).

S:\DOCS\ETA\ETA-2165.DOC/cfg/062104

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	